Jaguar Health, Inc.
Key Metrics
- Previous Close
- $0.38
- 52-Week Range
- $0.33 – $981.75
- Market Cap
- $4.71M
- P/E (TTM)
- —
- EPS (TTM)
- -4012.65
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.01
- PEG Ratio
- —
- Return on Equity
- -288.07%
- Return on Assets
- -36.41%
- Gross Margin
- 81.47%
- Operating Margin
- -88.20%
- Profit Margin
- -120.44%
- Current Ratio
- 1.28
- Debt/Equity
- 0.19
- Total Debt
- $3.52M
- Free Cash Flow
- $-280.50K
- Revenue Growth
- -24.00%
- Earnings Growth
- —
- Enterprise Value
- $-3.47M
Market Snapshot
About
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing plant-based prescription medicines for gastrointestinal distress. The company markets Mytesi, a prescription medicine for the symptomatic relief of diarrhea in adults living with HIV/AIDS on antiretroviral therapy. Jaguar is also developing Crofelemer for additional indications including cancer therapy-related diarrhea and congenital diarrheal disorders. The company leverages sustainable botanical ingredients from South American rainforests in its drug development efforts.